X-THERMA
Founded in 2017 and based in Hercules, California, X-Therma is a pioneering cryopreservation startup. The company uses technology inspired by antifreeze proteins found in Arctic organisms to enable the safe storage of organs, tissues and cells at sub-zero temperatures, preventing damage to biological materials.
Its flagship solution, XT-ViVo®, uses biomimetic peptoids to prevent the formation of ice crystals, protecting tissues and ensuring storage at sub-zero temperatures. This approach has the potential to significantly improve transplant outcomes and reduce waiting lists. In 2022, XT-ViVo® was granted Breakthrough Device status by the FDA for kidney preservation up to 120 hours. The company is currently working to complete pre-clinical studies in order to enter clinical trials.
XT-Thrive® is a solution already available in the unregulated cell cryopreservation market. This product, which has started to generate revenues, is particularly suited to applications in gene therapy, biobanking and tissue culture.
Among the products in development, XT-Hope aims to revolutionise the in vitro fertilisation (IVF) market with a vitrification solution that not only improves the survival rate of cryopreserved embryos, but also their quality and implantability.
The latest $22.4 million investment round, in which LIFTT participated, will be used to commercialise XT-Thrive®, complete pre-clinical studies for XT-ViVo® and initiate clinical trials, with the aim of changing the future of biopreservation by revolutionising the fields of organ transplantation, regenerative medicine and cell therapy.
Round
LIFTT Investment
In portfolio: Q4 2024
Fase Venture: Start-up
